Logo image of EDIT

EDITAS MEDICINE INC (EDIT) Stock Fundamental Analysis

NASDAQ:EDIT - Nasdaq - US28106W1036 - Common Stock - Currency: USD

2.835  -0.04 (-1.56%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to EDIT. EDIT was compared to 558 industry peers in the Biotechnology industry. Both the profitability and financial health of EDIT have multiple concerns. EDIT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EDIT has reported negative net income.
In the past year EDIT has reported a negative cash flow from operations.
In the past 5 years EDIT always reported negative net income.
EDIT had a negative operating cash flow in each of the past 5 years.
EDIT Yearly Net Income VS EBIT VS OCF VS FCFEDIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

EDIT has a worse Return On Assets (-95.29%) than 74.19% of its industry peers.
EDIT has a worse Return On Equity (-402.48%) than 75.27% of its industry peers.
Industry RankSector Rank
ROA -95.29%
ROE -402.48%
ROIC N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
EDIT Yearly ROA, ROE, ROICEDIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EDIT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDIT Yearly Profit, Operating, Gross MarginsEDIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

2

2. Health

2.1 Basic Checks

EDIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EDIT has more shares outstanding
EDIT has more shares outstanding than it did 5 years ago.
EDIT has a worse debt/assets ratio than last year.
EDIT Yearly Shares OutstandingEDIT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EDIT Yearly Total Debt VS Total AssetsEDIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

EDIT has an Altman-Z score of -9.25. This is a bad value and indicates that EDIT is not financially healthy and even has some risk of bankruptcy.
EDIT's Altman-Z score of -9.25 is on the low side compared to the rest of the industry. EDIT is outperformed by 70.79% of its industry peers.
EDIT has a Debt/Equity ratio of 0.79. This is a neutral value indicating EDIT is somewhat dependend on debt financing.
EDIT has a worse Debt to Equity ratio (0.79) than 75.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -9.25
ROIC/WACCN/A
WACC9.51%
EDIT Yearly LT Debt VS Equity VS FCFEDIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

EDIT has a Current Ratio of 3.08. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EDIT (3.08) is worse than 63.80% of its industry peers.
EDIT has a Quick Ratio of 3.08. This indicates that EDIT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.08, EDIT is doing worse than 62.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.08
Quick Ratio 3.08
EDIT Yearly Current Assets VS Current LiabilitesEDIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for EDIT have decreased strongly by -44.76% in the last year.
EDIT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.37%.
Measured over the past years, EDIT shows a quite strong growth in Revenue. The Revenue has been growing by 9.50% on average per year.
EPS 1Y (TTM)-44.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.05%
Revenue 1Y (TTM)-48.37%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%310.4%

3.2 Future

Based on estimates for the next years, EDIT will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.24% on average per year.
The Revenue is expected to decrease by -14.13% on average over the next years. This is quite bad
EPS Next Y36.3%
EPS Next 2Y26.58%
EPS Next 3Y17.18%
EPS Next 5Y10.24%
Revenue Next Year-63.88%
Revenue Next 2Y-43.51%
Revenue Next 3Y-21.16%
Revenue Next 5Y-14.13%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EDIT Yearly Revenue VS EstimatesEDIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
EDIT Yearly EPS VS EstimatesEDIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EDIT. In the last year negative earnings were reported.
Also next year EDIT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDIT Price Earnings VS Forward Price EarningsEDIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDIT Per share dataEDIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as EDIT's earnings are expected to grow with 17.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.58%
EPS Next 3Y17.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDIT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDITAS MEDICINE INC

NASDAQ:EDIT (7/14/2025, 10:19:54 AM)

2.835

-0.04 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners57.42%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change-0.17%
Market Cap237.32M
Analysts71.43
Price Target3.44 (21.34%)
Short Float %10.1%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-52.14%
Min EPS beat(2)-53.11%
Max EPS beat(2)-51.16%
EPS beat(4)1
Avg EPS beat(4)-29.25%
Min EPS beat(4)-53.11%
Max EPS beat(4)1.53%
EPS beat(8)4
Avg EPS beat(8)-4.69%
EPS beat(12)7
Avg EPS beat(12)-1.53%
EPS beat(16)11
Avg EPS beat(16)2.69%
Revenue beat(2)1
Avg Revenue beat(2)269.96%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)546.84%
Revenue beat(4)1
Avg Revenue beat(4)88.12%
Min Revenue beat(4)-97.34%
Max Revenue beat(4)546.84%
Revenue beat(8)3
Avg Revenue beat(8)116.07%
Revenue beat(12)6
Avg Revenue beat(12)99.39%
Revenue beat(16)9
Avg Revenue beat(16)86.46%
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.35%
EPS NY rev (1m)-5.16%
EPS NY rev (3m)-18.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)29.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)47.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.62
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 3.8
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-2.57
FCFYN/A
OCF(TTM)-2.49
OCFYN/A
SpS0.43
BVpS0.75
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -95.29%
ROE -402.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.65%
ROA(5y)-38.33%
ROE(3y)-93.86%
ROE(5y)-69.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.9%
Cap/Sales 19.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.08
Quick Ratio 3.08
Altman-Z -9.25
F-Score1
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)98.25%
Cap/Depr(5y)126.71%
Cap/Sales(3y)18.09%
Cap/Sales(5y)18.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-44.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.05%
EPS Next Y36.3%
EPS Next 2Y26.58%
EPS Next 3Y17.18%
EPS Next 5Y10.24%
Revenue 1Y (TTM)-48.37%
Revenue growth 3Y8.16%
Revenue growth 5Y9.5%
Sales Q2Q%310.4%
Revenue Next Year-63.88%
Revenue Next 2Y-43.51%
Revenue Next 3Y-21.16%
Revenue Next 5Y-14.13%
EBIT growth 1Y-11.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.5%
EBIT Next 3Y22.48%
EBIT Next 5YN/A
FCF growth 1Y-28.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.04%
OCF growth 3YN/A
OCF growth 5YN/A